Tag: high-risk melanoma options

Home / high-risk melanoma options

Categories

Nivolumab is approved by the FDA for adjuvant treatment of Stage IIB/C melanoma

Nov 2023: Nivolumab (Opdivo, Bristol-Myers Squibb Company) was granted approval by the Food and Drug Administration as an adjuvant therapy for Stage IIB/C melanoma in patients 12 years of age and ol...
high-risk-melanoma-options

Scan the code